title: Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm.
abstract: Sipuleucel-T is an autologous cellular immunotherapy approved in the US for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). This significant advance for mCRPC treatment provides healthcare professionals with another effective therapy to extend survival. As an immunotherapy, sipuleucel-T possesses specific characteristics differentiating it from traditional therapies. At a roundtable meeting of experts, sipuleucel-T data were discussed, focusing on interpretation and clinical implications. Important differences between immunotherapies and traditional therapies were explored, e.g., mode of action, outcomes, data consistency and robustness, timing of sipuleucel-T treatment, and future perspectives in areas such as short-term markers of long-term benefit.
authors.affiliation: Genitourinary Malignancies Branch and Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health , Bethesda, MD, USA.
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley
authors.affiliation: Radboud University Nijmegen Medical Center , Nijmegen, The Netherlands.
authors.forename: Peter
authors.initials: P
authors.lastname: Mulders
authors.affiliation: Düsseldorf University, Medical Faculty , Düsseldorf, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Albers
authors.affiliation: Jackson Laboratory for Genomic Medicine , Farmington, CT, USA.
authors.forename: Jacques
authors.initials: J
authors.lastname: Banchereau
authors.affiliation: Department of Radiation Therapy, C.H.U. Grenoble , Grenoble, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Bolla
authors.affiliation: Department of Tumor Biology, University Medical Center Hamburg Eppendorf , Hamburg, Germany.
authors.forename: Klaus
authors.initials: K
authors.lastname: Pantel
authors.affiliation: Barts Cancer Institute, Queen Mary University of London , London, UK.
authors.forename: Thomas
authors.initials: T
authors.lastname: Powles
keywords: Clinical trials; immune responses; immunotherapy; prostate cancer; sipuleucel-T